Abstract LB460: Characterization of ARTS-051, a potent and selective Werner helicase inhibitor effective against a broad range of MSI-H colorectal cancer models
Abstract Microsatellite instability, caused by defects in DNA mismatch repair, is a feature of many cancers including colorectal, gastric, endometrial, and ovarian. Werner helicase (WRN), a RecQ helicase involved in genome maintenance and DNA damage repair, is essential for cancer cells with high microsatellite instability (MSI-H), making it a promising target for the treatment of MSI-H cancers. Here we characterize a new non-covalent WRN inhibitor, ARTS-051, which is potent and selective across multiple MSI-H colorectal cancer models. In enzymatic assays, ARTS-051 inhibits WRN ATPase and helicase activity and displays over 2000-fold selectivity for WRN over the most closely related RecQ helicase, BLM. ARTS-051 also demonstrates excellent potency against the proliferation of both highly sensitive MSI-H cell lines (HCT116 and SW48) and less sensitive MSI-H cell lines (SNU-407 and RKO). At the same time, ARTS-051 exhibits more than 90-fold selectivity over microsatellite stable (MSS) cell line HT29. Mutation of WRN C727 confers resistance to existing WRN inhibitors, making it a potential vulnerability of these inhibitors. In contrast, ARTS-051 is effective in WRN C727S and C727A mutant HCT116 cells, outperforming the clinical stage WRN inhibitor HRO761 by nearly 10-fold. In multiple MSI-H cell-line derived mouse models including the less sensitive RKO and mutant WRN C727S HCT116 models, treatment with ARTS-051 leads to tumor regression without significant toxicity. Additionally, ARTS-051 displays good drug-like properties including solubility, permeability, and liver microsome stability, as well as a positive PK profile with low clearance and good oral exposure across species, supporting favorable clinical dose projections. Taken together, these data show that ARTS-051 is a promising WRN inhibitor with best-in-class potential to treat MSI-H colorectal cancers. Citation Format: Christine Moomau, Jiaqi Liang, Jian Lin, Xiaozhi Yang, Wenheng Liang, John Campbell, Yipin Lu, David Pirovich, Tao Ji, Lina Gu, Fang Li, Yaoyu Chen, Xiang Zhai. Characterization of ARTS-051, a potent and selective Werner helicase inhibitor effective against a broad range of MSI-H colorectal cancer models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr LB460.
Authors
- Xiaozhi Taro Yang (ORCID: https://orcid.org/0000-0002-9134-8752)
- Yaoyu Chen (ORCID: https://orcid.org/0000-0003-4587-0539)
- Xiang Zhai (ORCID: https://orcid.org/0009-0001-6010-8609)
- David B. Pirovich (ORCID: https://orcid.org/0000-0002-9501-2770)
- Yipin Lu
- Tao Ji (ORCID: https://orcid.org/0000-0003-4522-8888)
- Lina Gu
- Wenheng Liang
- Fang Li
- Christine Moomau
- Jiaqi Liang
- John Campbell
- Jian Lin
Institutions
- Bioscience (China) (CN)
- Cytori Therapeutics (United States) (US)
Publication Details
- Journal
- Cancer Research
- Published
- 2026-04-17
- DOI
- https://doi.org/10.1158/1538-7445.am2026-lb460
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00